Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from ...

It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is ...

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology ... The company was founded by ...

Headquartered in Dublin, Ireland, ICON Public Limited Company (NASDAQ ... tighter management of R&D spend by pharmaceuticals, less biotechnology funding availability, a greater number of project ...